Received Jan 7, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 2 | EN6204 | — |
Lung cancer; This is a spontaneous report received from a Consumer or other non HCP. A 68-year-old male patient received BNT162b2 (BNT162B2), on 13Mar2021 at 13:00 as dose 2, single (Lot number: EN6204) at the age of 64 years for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), for Covid-19 Immunization. The following information was reported: LUNG NEOPLASM MALIGNANT (medically significant, life threatening) with onset 03Mar2025, outcome "unknown", described as "Lung cancer". Therapeutic measures were taken as a result of lung neoplasm malignant. Additional information: Patient was diagnosed with Lung cancer March 2025 and AE resulted in Life threatening illness (immediate risk of death from the event). Patient was treated with Chemo and lobectomy.